Invesco
HUMA icon

Invesco’s Humacyte HUMA Stock Holding History

Invesco’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105K Buy
172,435
+133,611
+344% +$139K ﹤0.01% 3617
2025
Q4 		$37.3K Buy
38,824
+5,079
+15% +$7.19K ﹤0.01% 3726
2025
Q3 		$58.7K Buy
33,745
+3,952
+13% +$7.74K ﹤0.01% 3736
2025
Q2 		$62.3K Sell
29,793
-352
-1% -$676 ﹤0.01% 3708
2025
Q1 		$51.4K Sell
30,145
-782
-3% -$2.94K ﹤0.01% 3695
2024
Q4 		$156K Buy
30,927
+1,438
+5% +$7.12K ﹤0.01% 3557
2024
Q3 		$160K Buy
29,489
+3,239
+12% +$21.4K ﹤0.01% 3556
2024
Q2 		$126K Buy
26,250
+4,301
+20% +$22.4K ﹤0.01% 3720
2024
Q1 		$68.3K Buy
21,949
+856
+4% +$2.88K ﹤0.01% 3780
2023
Q4 		$59.9K Sell
21,093
-2,551
-11% -$6.55K ﹤0.01% 3738
2023
Q3 		$69.3K Buy
23,644
+60
+0.3% +$199 ﹤0.01% 3770
2023
Q2 		$67.5K Buy
23,584
+336
+1% +$1.21K ﹤0.01% 3789
2023
Q1 		$71.8K Sell
23,248
-3,133
-12% -$8.91K ﹤0.01% 3731
2022
Q4 		$55.7K Buy
26,381
+6,356
+32% +$19.3K ﹤0.01% 3905
2022
Q3 		$66K Buy
20,025
+758
+4% +$2.91K ﹤0.01% 3893
2022
Q2 		$63K Buy
+19,267
New +$107K ﹤0.01% 3946

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Invesco's HUMA Position: Q1 2026 in Review

Invesco increased its Humacyte (HUMA) stake by 344% in Q1 2026, buying an estimated $139K and bringing the position to 172,435 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #3617.

Invesco first reported a position in HUMA in Q2 2022 and has held it in 16 quarters since. The position peaked at $160K in Q3 2024. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Invesco held 172,435 shares of Humacyte worth $105K as of Q1 2026.
  • Invesco bought 133,611 Humacyte shares in Q1 2026, an estimated $139K.
  • Humacyte made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3617 holding.
  • Invesco first reported a position in Humacyte in Q2 2022 and has held it in 16 quarters since.
  • Invesco's Humacyte position peaked at $160K in Q3 2024.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.